Ble visst det jeg og. Antar at kursen vil holdes nede en stund til, blir nok ingen rep.emi. Men når sommeren får lagt seg og innsidehandlene kommer (?), vil vi vende kursen nordover.
Insiderkjøp hadde vært en meget solid signal, men de sitter på ekstremt mange opsjoner, så usikkert. Uansett har ikke aksjen varit så oversolgt siden 7.5 kr. Så att vi hvertfall kommer få en rekyl opp det er jag rimlig sikker på.
1 Like
MCAP 750 mill. Cash 370 mill?
Ut av Havyard og inn i Trvx med en liten pott på 18 nå. Synes den er litt oversolgt og skal nok fort over 20 igjen.
Nå er jag litt redd mine venner! Idag er første gangen ett innehav er større en 70% av swing porteføljen. Targovax blev det innehavet idag.
Dette skjer aldri ellers, men på mandag er jag tilbake i jobb og kmr ha svært lite tid til å trade. Så kjøper en posisjon i det innehavet jag har mest tro på de kommende 3-4 mnd. Finnes en stopp men en relativt stor en. Har også noen triggers på kjøp nedover.
Men nå føles det som allt er på plass for att Targovax ska nu oppover. Alle tekniske signaler finnes der, selskapet har hentet inn nok penger til 2 år fremover, ledningen tegner opsjoner og RSU isteden for lønn (noe som indikerer att de tror på høyere kurser), 3 nya read outs i år med solida resultater så langt.
Mega long mot 50-70 kr, ett bud kmr komme på Targovax i 2018 visst resultatene er solide.
Wish me luck.
4 Likes
Jeg sitter også dypt begravet i denne. Usikkert om jeg sitter mega long eller bare tilbake til 22-32. Det får tiden vise. Men har alltid tenkt at denne aksjen har stort potensiale i H2. 
Ja vi får se hvordan dette ender 
Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
Oslo, Norway, 30 June 2017: Targovax ASA (“Targovax” or the “Company”) has today
held an extraordinary general meeting. The general meeting approved all items on
the agenda, including the private placement announced by the Company on 8 June
2017 and the subsequent offering (the “Subsequent Offering”).
The share capital increase pertaining to the private placement is expected to be
registered on or about 6 July 2017, and, subject to approval of the listing
prospectus for shares issued in the private placement, the private placement
shares are expected to be listed and tradable on the Oslo Stock Exchange later
on the same date.
The commencement of the Subsequent Offering is also subject to a prospectus
being approved by the Norwegian Financial Supervisory Authority and published by
the Company. All details about the Subsequent Offering will be set out in the
prospectus, expected to be published no later than 3 July 2017.
The minutes of the extraordinary general meeting are attached to this
announcement and can also be found on the Company’s website, www.targovax.com.
Lausanne, Switzerland and Stockholm, Sweden, 30 June 2017:
Reference is made to the stock exchange announcement dated
30 June 2017 regarding the approval of the private placement
announced on 8 June 2017 by the extraordinary general
meeting of Targovax ASA (“Targovax”).On behalf of HealthCap V LP fund and OFCO Club V, HealthCap
V GP SA and OFP V Advisor AB subscribed for and was
allocated a total of 1,250,000 shares in Targovax in the
private placement. The subscription price was NOK 20 per
share. The entities have a parallel investment agreement and
is thus acting in concert, cf. section 2-5 no. 5 of the
Norwegian Securities Trading Act. Johan Christenson and Per
Samuelsson, employed by the exclusive advisor to HealthCap V
LP fund, are members of the board of directors of Targovax.
Following registration of the share capital increase
pertaining to the private placement in the Norwegian
Register of Business Enterprises, which is expected to take
place on or about 6 July 2017, HealthCap V LP fund and OFCO
Club V, will own 12,405,584 shares in Targovax on a
consolidated basis, representing approximately 23.75% of the
shares and votes in the Company, divided between them as
follows:
- HealthCap V LP: 12,219,500 shares (23.39%)
- OFCO Club V: 186,084 shares (0.36%)
This information is subject to the disclosure requirements
pursuant to sections 4-2 and 4-3 of the Norwegian Securities
Trading Act.
http://www.newsweb.no/newsweb/search.do?messageId=430707
Bull!
2 Likes
Blir det rep.emi altså?
Oslo, 30 June 2017: Reference is made to the stock exchange announcements by
Targovax ASA (“Targovax” or the “Company”) regarding the private placement and
subsequent offering approved by the extraordinary general meeting of the Company
earlier today.
Approval and availability of the Prospectus:
The Financial Supervisory Authority of Norway has today approved a prospectus
prepared by the Company (the “Prospectus”) in connection with the listing of the
private placement shares and subsequent offering (the “Subsequent Offering”) and
listing of up to 2,000,000 new shares in the Company each with a par value of
NOK 0.10 (the “Offer Shares”). The Prospectus has been passported to Sweden
through a notification to the Swedish Financial Supervisory Authority
(Sw.:Finansinspektionen) in accordance with Section 7-9 of the Norwegian
Securities Trading Act.
The prospectus will be available on the following websites: www.targovax.com,
www.dnb.no/emisjoner and www.abgsc.no. Hard copies of the Prospectus are
available at the offices of Targovax ASA, Lilleakerveien 2 C, 0283 Oslo, Norway
or may be obtained by contacting ABG Sundal Collier at +47 22 01 60 00 or DNB
Markets at +47 23 26 81 01.
The private placement shares:
The share capital increase pertaining to the private placement is expected to be
registered on or about 6 July 2017, and the private placement shares are
expected to be listed and tradable on the Oslo Stock Exchange later on the same
date.
The Subsequent Offering:
- The Subsequent Offering consists of an offer by the Company to issue up to
2,000,000 Offer Shares, raising approximately NOK 40 million in gross
proceeds to the Company if all Offer Shares are issued.- Eligible Shareholders, being shareholders of the Company as of 8 June 2017
(and being registered as such in the VPS on 12 June 2017 pursuant to the two
days’ settlement procedure in the VPS (the Record Date)), who were not
allocated shares in the private placement and who are not resident in a
jurisdiction where such offering would be unlawful, or for jurisdictions
other than Norway and Sweden, would require any filing, registration or
similar action, will be granted transferable subscription rights (the
"Subscription Rights") that, subject to applicable law, provide preferential
rights to subscribe for and be allocated Offer Shares at the Subscription
Price (as defined below).- The Eligible Shareholders will be granted 0.09598 Subscription Rights for
each existing share registered as held by such Eligible Shareholders as of
the Record Date, rounded down to the nearest whole Subscription Right. Each
whole Subscription Right provides a preferential right to subscribe for, and
be allocated, one Offer Share at the Subscription Price, subject to
applicable securities laws. Oversubscription and subscription without
subscription rights is permitted.- The Subscription Rights will be listed and tradable on the Oslo Stock
Exchange under the ticker “TRVX T” from 3 July 2017 until 16:30 hours (CET)
on 12 July 2017. The Subscription Rights will be registered in the VPS with
ISIN NO0010799604.- The subscription period will commence on 3 July 2017 and expire at 16:30
hours (CET) on 14 July 2017 (the “Subscription Period”).- The Subscription Price in the Subsequent Offering is NOK 20 per Offer Share,
being the same as the subscription price in the private placement completed
on 8 June 2017.- The Subscription Rights are expected to have an economic value if the
Company’s shares trade above the Subscription Price during the Subscription
Period. Eligible Shareholders who do not use their Subscription Rights will
experience a dilution of their shareholding in the Company.- The Subscription Rights, including acquired Subscription Rights, must be
sold before 12 July 2017 at 16:30 (CET) or used to subscribe for Offer
Shares before the expiry of the Subscription Period on 14 July 2017 at
16:30 hours (CET). Subscription Rights that are not sold before 16:30 (CET)
on 12 July 2017 or used to subscribe for Offer Shares before 16:30 hours
(CET) on 14 July 2017 will have no value and will lapse without compensation
to the holder.- The payment for Offer Shares allocated to a subscriber falls due on 20 July
2017.- The share capital increase pertaining to the Subsequent Offering is expected
to be registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret) on or about 24 July 2017. The Offer Shares are expected
to be delivered to the subscribers and commence trading on the Oslo Stock
Exchange on the same day.
ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA, are acting as
Managers for the private placement and the Subsequent Offering.
For further information, please contact:
Erik Digman Wiklund, CFO
Phone: +47 413 33 563
Email: [email protected]
Helt greit det. Ekstra kapital, aksjonærvennlig og kursen vil trooolig ikke gå mye under 20 igjen om denne blir fulltegnet.
Bare å kjøpe under 20 nå for de av dere som sitter på gjerdet.
Done Snittet ned, kom inn på 19.20. Snittet er da fortsatt over 23, men sitter jo long
1 Like
nice tror det er bra deal!
Snittet ned til 21 i går. Bør være en bra inngang.
Hvad er der af triggere her i juli?
Etter Juli? I august meinar du?
August triggere er også fint.
Nei jag mener Juli. Emissjonen avsluttes 20 Juli, deretter lær trykket øke da fundamentala endres etter pengene kommet inn. Aksjen er ikke lengre verdt 20 kr. Fundamentale under kommende halvåret kmr endres etter studie resultaten. Allt avhenger av positive resultat.
1 Like